PRMT1 inhibitors and uses thereof

1. A method of therapeutic treatment of a PRMT1-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I-a) or (I-b):

or a pharmaceutically acceptable salt thereof,

wherein

X is N, Z is NR 4 , and Y is CR 5 ; or

X is NR 4 , Z is N, and Y is CR 5 ; or

X is CR 5 , Z is NR 4 , and Y is N; or

X is CR 5 , Z is N, and Y is NR 4 ;

R G is CF 3 or CF 2 H;

R 1 is hydrogen, halo, —CN, —NO 2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —(CR z R z ) n C(O)N(R B ) 2 , —OR A , —N(R B ) 2 , —SR A , —C(═O)R A , —C(O)OR A , —C(O)SR A , —C(O)N(R B ) 2 , —C(O)N(R B )N(R B ) 2 , —OC(O)R A , —OC(O)N(R B ) 2 , —NR B C(O)R A , —NR B C(O)N(R B ) 2 , —NR B C(O)N(R B )N(R B ) 2 , —NR B C(O)OR A , —SC(O)R A , —C(═NR B )R A , —C(═NNR B )R A , —C(═NOR A )R A , —C(═NR B )N(R B ) 2 , —NR B C(═NR B )R B , —C(═S)R A , —C(═S)N(R B ) 2 , —NR B C(═S)R A , —S(O)R A , —OS(O) 2 R A , —SO 2 R A , —NR B SO 2 R A , or —SO 2 N(R B ) 2 ;

R 2 is hydrogen, halo, —CN, —NO 2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —OR A , —N(R B ) 2 , —SR A , —C(═O)R A , —C(O)OR A , —C(O)SR A , —C(O)N(R B ) 2 , —C(O)N(R B )N(R B ) 2 , —OC(O)R A , —OC(O)N(R B ) 2 , —NR B C(O)R A , —NR B C(O)N(R B ) 2 , —NR B C(O)N(R B )N(R B ) 2 , —NR B C(O)OR A , —SC(O)R A , —C(═NR B )R A , —C(═NNR B )R A , —C(═NOR A )R A , —C(═NR B )N(R B ) 2 , —NR B C(═NR B )R B , —C(═S)R A , —C(═S)N(R B ) 2 , —NR B C(═S)R A , —S(O)R A , —OS(O) 2 R A , —SO 2 R A , —NR B SO 2 R A , or —SO 2 N(R B ) 2 ;

R 6 is hydrogen, halo, —CN, —NO 2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —OR A , —N(R B ) 2 , —SR A , —C(═O)R A , —C(O)OR A , —C(O)SR A , —C(O)N(R B ) 2 , —C(O)N(R B )N(R B ) 2 , —OC(O)R A , —OC(O)N(R B ) 2 , —NR B C(O)R A , —NR B C(O)N(R B ) 2 , —NR B C(O)N(R B )N(R B ) 2 , —NR B C(O)OR A , —SC(O)R A , —C(═NR B )R A , —C(═NNR B )R A , —C(═NOR A )R A , —C(═NR B )N(R B ) 2 , —NR B C(═NR B )R B , —C(═S)R A , —C(═S)N(R B ) 2 , —NR B C(═S)R A , —S(O)R A , —OS(O) 2 R A , —SO 2 R A , —NR B SO 2 R A , or —SO 2 N(R B ) 2 ;

R 7 and R 8 are independently selected from the group consisting of hydrogen, halo, —CN, —NO 2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —OR A , —N(R B ) 2 , —SR A , —C(═O)R A , —C(O)OR A , —C(O)SR A , —C(O)N(R B ) 2 , —C(O)N(R B )N(R B ) 2 , —OC(O)R A , —OC(O)N(R B ) 2 , —NR B C(O)R A , —NR B C(O)N(R B ) 2 , —NR B C(O)N(R B )N(R B ) 2 , —NR B C(O)OR A , —SC(O)R A , —C(═NR B )R A , —C(═NNR B )R A , —C(═NOR A )R A , —C(═NR B )N(R B ) 2 , —NR B C(═NR B )R B , —C(═S)R A , —C(═S)N(R B ) 2 , —NR B C(═S)R A , —S(O)R A , —OS(O) 2 R A , —SO 2 R A , —NR B SO 2 R A , and —SO 2 N(R B ) 2 ; wherein at least one of R 7 and R 8 is not hydrogen;

each R A is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom;

each R B is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, and a nitrogen protecting group, or two R B groups are taken together with their intervening atoms to form an optionally substituted heterocyclic ring;

R 1 and R 2 are optionally taken together to form a carbocyclic, heterocyclic, or aryl ring; or

R 2 and R 8 are optionally taken together to form a carbocyclic, heterocyclic, or aryl ring; or

R 6 and R 7 are optionally taken together to form a carbocyclic, heterocyclic, or aryl ring;

R 3 is hydrogen, C 1-4 alkyl, or C 3-4 cycloalkyl;

R 4 is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-7 cycloalkyl, optionally substituted 4- to 7-membered heterocyclyl, or optionally substituted C 1-4 alkyl-Cy;

Cy is optionally substituted C 3-7 cycloalkyl, optionally substituted 4- to 7-membered heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R 5 is hydrogen, halo, —CN, optionally substituted C 1-4 alkyl, or optionally substituted C 3-4 cycloalkyl;

R x is optionally substituted C 1-4 alkyl or optionally substituted C 3-4 cycloalkyl;

R y is —NR B C(O)R A , —NR B SO 2 R A , or —(CR z R z ) n C(O)N(R B ) 2 ;

each R z is independently hydrogen or fluoro; and

n is 0, 1, 2, 3, or 4;

wherein the PRMT1-mediated disorder is selected from breast cancer, prostate cancer, lung cancer, colon cancer, bladder cancer, leukemia, lymphoma, diabetes mellitus, kidney failure, coronary heart disease, oculopharyngeal muscular dystrophy, and amyotrophic lateral sclerosis.

2. The method of claim 1 wherein R 1 is hydrogen, —OR A , —CN, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted carbocyclic.

3. The method of claim 1 , wherein R 2 is hydrogen, —OR A , —CN, halo, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted carbocyclic.

4. The method of claim 1 , wherein R 7 is hydrogen and R 8 is not hydrogen or wherein R 7 is not hydrogen and R 8 is hydrogen.

5. The method of claim 1 , wherein R 3 is hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, or cyclobutyl.

6. The method of claim 1 , wherein R 4 is hydrogen or optionally substituted C 1-6 alkyl.

7. The method of claim 1 , wherein R 5 is hydrogen or optionally substituted C 1-4 alkyl.

8. The method of claim 1 , wherein R x is methyl, ethyl, propyl, butyl, isopropyl, hydroxyethyl, methoxyethyl, cyclopropyl, or cyclobutyl.

9. The method of claim 1 , wherein the compound is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

10. The method of claim 1 , wherein the PRMT1-mediated disorder is selected from breast cancer, prostate cancer, lung cancer, colon cancer, bladder cancer, leukemia, and lymphoma.

11. The method of claim 10 , wherein the PRMT1-mediated disorder is leukemia.

12. The method of claim 10 , wherein the PRMT1-mediated disorder is lymphoma.

13. The method of claim 1 , wherein the PRMT1-mediated disorder is selected from diabetes mellitus, kidney failure, coronary heart disease, oculopharyngeal muscular dystrophy, and amyotrophic lateral sclerosis.